News

Xenazine is the first and only FDA-approved treatment specifically developed for any Huntington’s disease-related symptom, the company said. Paul Dreyer, president of S&R, said: “In recent months, the

In this role, Mr Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for

The transaction was structured as an asset purchase under which AngioDynamics will pay $1.75 million in cash for the assets of the business plus a contingent payment based

Cleared for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff assay targets the toxin B gene, found in virtually all toxigenic Clostridium

Utilizing more than 1,200 patient samples from the Quasar trial, the validation study will use prospectively defined endpoints to assess the clinical utility of the Oncotype DX colon

Elekta Compact is a competitive linear accelerator for high-quality conventional radiotherapy, configured for countries in need of rapid build-up of additional treatment capacity, said Elekta. Elekta Compact is

Under the terms of the agreement, Dor will sell 20 million common shares together with a five-year warrant to purchase up to 200 million shares of Dor common

Under the terms of the settlement agreements, Warner Chilcott has granted Watson a non-exclusive license to the US patents covering Loestrin 24 Fe and Femcon Fe (norethindrone, ethinyl

Tiopronin tablets are prescribed in several countries for the treatment of acute and chronic hepatitis B, and for the relief of drug-induced liver injury. However, this drug can